These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. Estrada AA; Chan BK; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chen H; Dominguez SL; Dotson J; Drummond J; Flagella M; Fuji R; Gill A; Halladay J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Liu X; Lyssikatos JP; Medhurst AD; Moffat JG; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Wong S; Zhang S; Zhang X; Zhu H; Sweeney ZK J Med Chem; 2014 Feb; 57(3):921-36. PubMed ID: 24354345 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of LRRK2: from kinase to substrate. Lobbestael E; Baekelandt V; Taymans JM Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873 [TBL] [Abstract][Full Text] [Related]
10. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290 [TBL] [Abstract][Full Text] [Related]
11. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745 [TBL] [Abstract][Full Text] [Related]
13. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Yun H; Heo HY; Kim HH; DooKim N; Seol W Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311 [TBL] [Abstract][Full Text] [Related]
14. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
15. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252 [TBL] [Abstract][Full Text] [Related]
16. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Ray S; Liu M Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and Preliminary Evaluation of [ Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783 [TBL] [Abstract][Full Text] [Related]
18. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease? Taymans JM Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782 [TBL] [Abstract][Full Text] [Related]
19. Chemoproteomics Reveals the Antiproliferative Potential of Parkinson's Disease Kinase Inhibitor LRRK2-IN-1 by Targeting PCNA Protein. Li W; Zhou Y; Tang G; Wong NK; Yang M; Tan D; Xiao Y Mol Pharm; 2018 Aug; 15(8):3252-3259. PubMed ID: 29993254 [TBL] [Abstract][Full Text] [Related]